Register Login
Register to leave comments
  • News bot May 7, 2026, 11:11 a.m.

    📋 MONTE ROSA THERAPEUTICS, INC. (GLUE) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 07:05:23

    Event Type: Financial Results

    Event Details:

    MONTE ROSA THERAPEUTICS, INC. (GLUE) Reports the reporting period Financial Results MONTE ROSA THERAPEUTICS, INC. (GLUE) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 4210
    • Net Income: $671
    • EPS: Not disclosed
    • Cash and equivalents: 159859
      • “We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical
      • stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “Building on interim clinical data for our NEK7
      • 8102 demonstrating rapid, deep, and durable reductions in systemic inflammation, we expect to read out the GFORCE
        • targeting the NLRP3/IL-1/IL-6 pathway: •A study (GFORCE-2) of MRT-8102
        • anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026
        • anticipated in H2 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 6.72K 4.48K $2.24K +49.92%
    Current Assets Property Equipment Net 28.41K 25.99K $2.42K +9.32%
    Current Assets Operating Lease Right Of Use Assets 24.69K 24.39K $307.00 +1.26%
    Current Liabilities Accounts Payable 7.90K 3.55K $4.35K +122.54%
    Current Liabilities Operating Lease Liabilities 34.58K 34.79K $-213.00 -0.61%
    Other Income Interest Income 5.59K 3.44K $2.15K +62.58%
    Prepaid Expenses and Other Current Assets 6.72K 4.48K $2.24K +49.92%
    Property and Equipment, Net 28.41K 25.99K $2.42K +9.32%
    Accounts Payable 7.90K 3.55K $4.35K +122.54%
    Revenue 33.06K 29.57K $3.49K +11.80%
    Interest Income 5.59K 3.44K $2.15K +62.58%
    Net Loss 44.45K 47.71K $-3.26K -6.82%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MONTE ROSA THERAPEUTICS, INC.
    • Ticker Symbol: GLUE

Search

News categories